• 58% of healthtech launches fail due to misaligned market needs and regulatory gaps. • Structural issues: fragmented stakeholder collaboration and unclear value propositions hinder adoption. • Strategic missteps include late market entry, inadequate pricing models, and weak evidence generation. • Intelligent decision‑making tools can map regulatory pathways and forecast payer acceptance. • Early data capture and real‑world evidence accelerate reimbursement decisions and market access. • Cross‑functional teams that integrate clinical, commercial, and regulatory expertise improve launch success.
Article Summaries:
- MedCity News reports that more than half of new drug launches fail, citing a 58% failure rate. The article identifies structural and strategic factors-such as fragmented stakeholder coordination, inadequate market‑access planning, and insufficient real‑world evidence generation-that contribute to these setbacks. It then outlines actionable strategies to improve launch outcomes, including early integration of market‑access teams, data‑driven decision‑making, and adaptive regulatory engagement. By accelerating intelligent decision‑making throughout the development pipeline, the piece argues that companies can reduce launch failures and achieve faster, more reliable market access.
Sources: